Go Pro
→ Why the Treasury still prices gold at 42 dollars an ounce (From Golden Portfolio) (Ad)tc pixel Free ATRA Stock Alerts

Atara Biotherapeutics (ATRA) Stock Forecast & Price Target

Atara Biotherapeutics logo
$9.76 +0.23 (+2.41%)
As of 09/4/2026 04:00 PM Eastern
Compare

Atara Biotherapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy
Based on 4 Analyst Ratings
Sell
1
Hold
1
Buy
2

Based on 4 Wall Street analysts who have issued ratings for Atara Biotherapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 1 has given a sell rating, 1 has given a hold rating, 1 has given a buy rating, and 1 has given a strong buy rating for ATRA.

Consensus Price Target

$9.50
-2.66% Downside
According to the 4 analysts' twelve-month price targets for Atara Biotherapeutics, the average price target is $9.50. The highest price target for ATRA is $13.00, while the lowest price target for ATRA is $6.00. The average price target represents a forecasted downside of -2.66% from the current price of $9.76.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ATRA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Atara Biotherapeutics and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ATRA Analyst Ratings Over Time

TypeCurrent Forecast
9/6/25 to 9/6/26		1 Month Ago
8/7/25 to 8/7/26		3 Months Ago
6/8/25 to 6/8/26		1 Year Ago
9/6/24 to 9/6/25
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$9.50$9.50$9.50$21.00
Forecasted Upside-2.66% Downside12.43% Upside-0.84% Downside62.66% Upside
Consensus RatingModerate BuyHoldHoldModerate Buy

ATRA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ATRA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Atara Biotherapeutics Stock vs. The Competition

TypeAtara BiotherapeuticsHealthcare CompaniesBroader Market
Consensus Rating Score
2.50
2.30
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside-2.66% Downside928.70% Upside14.03% Upside
News Sentiment Rating
Very Positive News

See Recent ATRA News
Positive News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
8/24/2026
TD Cowen logo
TD Cowen
3 of 5 stars
 UpgradeStrong-Buy
8/18/2026
Weiss Ratings logo
Weiss Ratings
5 of 5 stars
 UpgradeSell (E+) ➝ Sell (D-)
5/18/2026
Freedom Capital logo
Freedom Capital
Not Rated
 UpgradeStrong Sell ➝ Hold
5/8/2026
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
John Newman
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Set TargetHold ➝ Buy$6.00 ➝ $13.00+30.92%
1/13/2026
New Street Research logo
New Street Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Set Target$6.00+37.46%
1/28/2025
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Robert Burns
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Reiterated RatingNeutral
1/21/2025
Rodman & Renshaw logo
Rodman & Renshaw
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
T. Butler
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 01:51 AM ET.


ATRA Forecast - Frequently Asked Questions

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Atara Biotherapeutics is $9.50, with a high forecast of $13.00 and a low forecast of $6.00.

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There is currently 1 sell rating, 1 hold rating, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ATRA shares.

According to analysts, Atara Biotherapeutics's stock has a predicted downside of -2.66% based on their 12-month stock forecasts.

Over the previous 90 days, Atara Biotherapeutics's stock had 3 upgrades and 2 downgrades by analysts.

Atara Biotherapeutics has been rated by research analysts at TD Cowen, and Weiss Ratings in the past 90 days.

Analysts like Atara Biotherapeutics more than other "healthcare" companies. The consensus rating for Atara Biotherapeutics is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ATRA compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Atara Biotherapeutics Recommendations


MarketBeat monitors more than a dozen sources for Atara Biotherapeutics analyst ratings, with the most recent rating issued on 8/24/2026.
From Our Partners
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
This looks like plywood. It's not.
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Why the Treasury still prices gold at 42 dollars an ounce
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...
Golden Portfolio | Sponsoredtc pixel
How to Think About a $500K Roth Conversion and the 35% Bracket
For 2026, the 35 percent federal tax bracket starts at 512,450 dollars in taxable income for joint filers and ...
SmartAsset | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel